. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain. 2016 Dec;139(Pt 12):3217-3236. Epub 2016 Sep 27 PubMed. Correction.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Research Models

  1. Thy1-αSyn “Line 61” Mouse

Therapeutics

  1. Minzasolmin